⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034160 | 0.83 | P2RX7 (0.41) | — | |
| SCHEMBL24090502 | 0.68 | TSHR (0.38) | — | |
| SCHEMBL12644652 | 0.66 | — | — | |
| SCHEMBL11185896 | 0.65 | HTR6 (0.30) | — | |
| SCHEMBL19990184 | 0.64 | TSHR (0.57) | — | |
| SCHEMBL12644103 | 0.64 | APOBEC3A (0.38) | — | |
| SCHEMBL11238817 | 0.64 | ALDH1A1 (0.41) | — | |
| SCHEMBL2035397 | 0.64 | P2RX7 (0.40) | — | |
| SCHEMBL18723897 | 0.62 | TAAR1 (0.58) | — | |
| SCHEMBL18723576 | 0.62 | TAAR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220062229-A1 | METHODS OF TREATING SCHIZOPHRENIA | SUNOVION PHARMACEUTICALS INC. (US) | 2022-03-03 | — | — | US | disclosed |
| US-11129807-B2 | Methods of treating schizophrenia | SUNOVION PHARMACEUTICALS INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200129477-A1 | METHODS OF TREATING SCHIZOPHRENIA | SUNOVION PHARMACEUTICALS INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3252057-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2507245-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9351954-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351954-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160083399-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PGI DRUG DISCOVERY LLC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083399-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PGI DRUG DISCOVERY LLC. | 2016-03-24 | — | — | US | disclosed |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | PSYCHOGENICS INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | PSYCHOGENICS INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |